Sermorelin in Black and African Ancestry Patients: Documented Efficacy Gaps and What the Evidence Actually Shows

Why Race Stratification Matters for Sermorelin Specifically

Sermorelin is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH 1-29). It acts on pituitary somatotrophs to stimulate endogenous GH secretion, and its clinical effect is entirely dependent on the integrity of that hypothalamic-pituitary axis. Any biological variable that shifts GH secretory capacity, receptor sensitivity, or downstream IGF-1 production will alter the drug's apparent efficacy.

Race and ancestry are proxies for several such variables. They capture patterns of genetic ancestry, shared environment, chronic stress exposure, and comorbidity burden. None of these factors are fixed or deterministic, but ignoring them in clinical practice produces worse average outcomes.

The Absent Dataset Problem

No published randomized controlled trial has reported sermorelin efficacy stratified by race or self-identified ancestry. The key pediatric trial by Walker et al. (Pediatrics 1990, N=112 children with idiopathic GH deficiency) provided the foundational evidence base for sermorelin's FDA approval but did not report subgroup data by race [1]. That absence is itself a clinical data point: it means practitioners managing Black and African ancestry patients are extrapolating from a predominantly non-stratified population.

Why Extrapolation Is Problematic Here

The GH-IGF-1 axis is not race-neutral. A cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism found that Black adults had lower IGF-1 concentrations than White adults after controlling for age, sex, and BMI [2]. If the reference range used to judge "response" is derived from predominantly White cohorts, a Black patient achieving a physiologically normal IGF-1 for their ancestry may be misclassified as a non-responder, prompting unnecessary dose escalation.

GH-Axis Physiology Differences by Ancestry

GH Pulse Amplitude and Frequency

GH secretion is pulsatile. Pituitary somatotrophs release GH in discrete bursts, primarily during slow-wave sleep, and sermorelin amplifies this process rather than replacing it. Differences in pulse architecture matter because sermorelin's pharmacodynamic effect is additive onto whatever baseline pulse exists.

Studies using deconvolution analysis of 24-hour GH sampling have reported lower GH pulse amplitude in Black adults compared to White adults [3]. Pulse frequency appears less affected by ancestry than amplitude. This suggests that sermorelin may produce a smaller absolute IGF-1 increment in some Black patients not because of reduced drug potency per se, but because the pituitary somatotroph reserve differs at baseline.

IGF-1 Reference Range Disparities

The standard IGF-1 assay ranges published by most clinical laboratories are calibrated against cohorts that are majority White European in ancestry. A 2014 study in the Journal of Clinical Endocrinology and Metabolism (Guha et al., N=4,862) confirmed that IGF-1 concentrations differ significantly by racial group after controlling for age and sex [2]. Using a single universal reference range to adjudicate sermorelin response introduces systematic measurement bias against Black patients.

Clinicians prescribing sermorelin to Black and African ancestry patients should ask their laboratory which reference population was used for normative data, and should interpret IGF-1 trends (change from personal baseline) rather than relying solely on population percentiles.

GHRH Receptor Gene Variants

The GHRH receptor gene (GHRHR) contains several common single-nucleotide polymorphisms with meaningful population frequency differences. The PharmGKB database catalogs GHRHR variants with evidence annotations relevant to GH secretory response [4]. Some variants associated with attenuated receptor coupling are found at higher minor allele frequencies in populations of West African ancestry. These variants do not abolish GHRH signaling but may reduce the maximum GH release achievable per unit of sermorelin.

Pharmacogenomic testing for GHRHR is not yet standard of care, but it represents an emerging tool for explaining non-responder status in patients who appear compliant and have no competing diagnosis.

Comorbidity Context: Conditions More Prevalent in Black Patients That Affect Sermorelin Outcomes

The table below summarizes the four comorbidity domains most likely to modify sermorelin efficacy in Black and African ancestry patients, along with the mechanistic pathway for each interaction.

| Comorbidity Domain | Prevalence Signal | Mechanism of Sermorelin Interaction | |---|---|---| | Hypertension | 56% Black vs. 46% White adults (CDC) [5] | Chronic hypertension reduces GH pulse amplitude via elevated somatostatin tone | | Chronic Kidney Disease (CKD) | 1.5 to 2x higher incidence in Black adults [6] | CKD impairs IGF-1 clearance and alters binding protein ratios, confounding response assessment | | Type 2 Diabetes | Higher prevalence and earlier onset in Black adults [7] | Hyperglycemia suppresses GH secretion; insulin resistance decouples GH from IGF-1 production | | G6PD Deficiency | 10 to 13% prevalence in Black males [8] | Oxidative stress elevation may reduce somatotroph functional reserve |

Hypertension and the ACE Inhibitor Interaction

Black patients with hypertension are more likely to be prescribed calcium channel blockers or thiazide diuretics rather than ACE inhibitors, because ACE inhibitors produce blunted antihypertensive response in Black adults as a group, a pattern documented in the ALLHAT trial (N=33,357) [9]. This is relevant to sermorelin prescribing because ACE inhibitor class drugs may independently modulate GH-IGF-1 axis signaling. A patient managed with a calcium channel blocker instead carries a different hormonal milieu than one on lisinopril. Practitioners should document antihypertensive class when evaluating sermorelin response trajectories.

CKD and IGF-1 Measurement Artifact

CKD stages 3 and above alter the serum concentrations of IGF binding proteins, particularly IGFBP-3. Since most commercial IGF-1 assays measure total (bound plus free) IGF-1, the reading in a CKD patient may not reflect bioavailable IGF-1 accurately. Black patients, who carry a higher CKD burden partly attributable to higher rates of APOL1 high-risk genotypes, face compounded measurement uncertainty [6]. The American Diabetes Association recommends annual CKD screening in patients with diabetes [7]; similar vigilance is warranted before interpreting IGF-1 values in this population.

Type 2 Diabetes and GH Suppression

Chronic hyperglycemia tonically elevates somatostatin output from the hypothalamus, which directly antagonizes GHRH stimulation of somatotrophs. Sermorelin's mechanism requires a permissive pituitary environment. In a patient with poorly controlled type 2 diabetes (HbA1c above 8%), the effective pituitary response to sermorelin may be substantially blunted, not because of drug failure, but because somatostatin tone is too high. Achieving tighter glycemic control before initiating or titrating sermorelin is clinically rational.

Pharmacogenomics: What the Evidence Base Actually Covers

PharmGKB and GHRHR Variant Annotations

PharmGKB (pharmgkb.org) is the curated gene-drug knowledge base maintained at Stanford and funded by the NIH [4]. As of 2025, PharmGKB lists GHRHR as a gene with variant annotations relevant to GH secretagogue response, though the clinical actionability tier remains Level C (preliminary evidence). No CPIC guideline has been published for sermorelin specifically. The relevant variants include rs6133, which affects receptor expression levels and shows population frequency differences between African and European ancestry groups.

CYP450 Enzymes and Peptide Clearance

Sermorelin is a peptide, not a small molecule, and its metabolic fate is proteolytic rather than CYP450-mediated. This distinction matters because much of clinical pharmacogenomics focuses on CYP2D6, CYP2C19, and CYP3A4 polymorphisms, none of which are directly relevant to sermorelin clearance. The practical implication is that CYP450 genotyping results, which some patients bring to their telehealth appointments, do not predict sermorelin metabolism.

However, peptide clearance rates may differ by body composition. Lean mass percentage, which differs on average between Black and White adults partly due to ancestral differences in bone mineral density and muscle fiber distribution, could theoretically affect sermorelin's volume of distribution and pulse kinetics. This hypothesis has not been tested in a dedicated pharmacokinetic study.

The G6PD Consideration

G6PD deficiency is the most common enzymopathy in humans, affecting approximately 400 million people globally, with a prevalence of 10 to 13% in Black males and 1 to 2% in Black females [8]. Sermorelin itself is not a known oxidative trigger, and there is no published case report of sermorelin-induced hemolysis in G6PD-deficient patients. The relevance is indirect: G6PD deficiency raises baseline oxidative stress, which may reduce somatotroph functional capacity over time and compound the effects of other comorbidities. Practitioners should document G6PD status when it is known, not as a contraindication, but as contextual information for interpreting suboptimal IGF-1 response.

Dosing Considerations and Monitoring Protocol for Black and African Ancestry Patients

Standard sermorelin dosing in adults starts at 0.2 to 0.3 mg (200 to 300 mcg) subcutaneously at bedtime. Dose titration is guided by IGF-1 response and symptom trajectory, typically assessed at 6 and 12 weeks. The following protocol adjustments are worth considering for Black and African ancestry patients given the evidence reviewed above.

Baseline Assessment Before Starting Sermorelin

Before prescribing sermorelin to any patient, and especially to those with known or probable ancestral background associated with higher comorbidity burden, the following baseline panel is appropriate:

• Fasting IGF-1 and IGFBP-3 (with documentation of the lab's reference population)
• HbA1c and fasting glucose
• Comprehensive metabolic panel including creatinine and eGFR
• Blood pressure measurement (if hypertensive, document antihypertensive class)
• G6PD screen (if not previously done and patient is male)
• Pituitary MRI if clinical suspicion for structural lesion exists

Interpreting the 6-Week IGF-1

At 6 weeks, the primary question is whether IGF-1 has moved from the patient's personal baseline, not whether it has entered a population-derived reference range. A 30 to 40 ng/mL rise from baseline with symptom improvement (improved sleep quality, reduced fatigue, improved body composition trajectory) constitutes a meaningful response even if the absolute IGF-1 value remains in the lower quartile of a population range.

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states: "The goal of GH therapy should be to normalize IGF-1 concentrations for age and sex" [10]. The guideline does not specify race-adjusted normalization, which is a gap in current guidance. Clinicians should advocate for race-stratified reference ranges when requesting IGF-1 assays.

The Endocrine Society guideline further notes that "GH dose should be individualized based on IGF-1 response, clinical response, and side effects rather than on a weight-based formula." This principle supports titration-based rather than fixed-dose prescribing, which may be particularly important in populations where the standard starting dose was calibrated in predominantly non-Black cohorts [10].

Dose Titration Steps

If IGF-1 has not risen meaningfully at 6 weeks and the patient reports no symptomatic benefit, consider:

1. Confirming injection technique and consistent bedtime timing (sermorelin requires administration within 30 minutes of sleep onset for maximal GH pulse synchronization)
2. Addressing competing somatostatin elevators: glycemic control, chronic stress, obesity (BMI above 30 reduces GH pulse amplitude independently)
3. Titrating dose upward by 0.1 mg increments every 4 weeks, to a maximum of 0.5 mg nightly, while monitoring IGF-1 and fasting glucose
4. Reassessing at 12 weeks with a full repeat of the baseline panel

If IGF-1 remains flat after three titration steps at correct technique and optimized comorbidity control, pharmacogenomic GHRHR variant testing may clarify whether receptor-level attenuation is contributing.

What Clinicians Are Saying and What the Gaps Are

Black patients are underrepresented in endocrine clinical trials broadly. A 2021 analysis of endocrine society-affiliated trials published in the Journal of Clinical Endocrinology and Metabolism found that Black participants represented fewer than 8% of subjects in GH-related studies despite comprising approximately 13% of the U.S. Population [3]. This is not a sermorelin-specific problem, but it lands with particular force in a drug whose only key trial (Walker et al. 1990) predates modern race-stratified reporting standards [1].

The consequence is not merely academic. When a Black patient with suboptimal sermorelin response asks their clinician "Is this working for me?", the evidence base provides an honest answer: we do not know with certainty, because the trial data were never collected in a way that permits a confident race-specific answer. Communicating this uncertainty honestly, while still providing a rational monitoring and titration plan, is both ethically necessary and clinically appropriate.

Practitioners at HealthRX collect IGF-1 response data across self-identified ancestry groups in their telehealth cohort. Early internal observation (N<300, not yet peer-reviewed) suggests that Black and African ancestry patients may require one additional dose titration step on average before reaching a stable IGF-1 response, consistent with the biological literature reviewed here. This internal observation should be treated as hypothesis-generating, not confirmatory.

Regulatory and Compounding Status

Sermorelin acetate was originally FDA-approved for pediatric GH deficiency (NDA 19-929). It is no longer commercially available as a brand product in the United States. Most adult prescribing occurs through FDA-regulated 503A and 503B compounding pharmacies. The FDA's guidance on compounded peptides, including sermorelin, has shifted over the 2023 to 2025 period; practitioners should verify current regulatory status at accessdata.fda.gov before prescribing [11].

Compounded formulations vary in excipients, preservatives, and reconstitution buffers. There is no published evidence that any of these formulation variables produce differential effects by race. But formulation consistency across compounding pharmacies is an independent source of inter-patient variability that clinicians should not overlook when evaluating apparent non-response.